• Corrosion Science and Technology
• /
• 제8권5호
• /
• pp.197-202
• /
• 2009

The high toxicity of wax, oil, varnish and volatile corrosion inhibitor(VCI) corrosion inhibitors lead to an increasing interest in using non-toxic alternatives such as anti-corrosive film. This study aims to investigate the possibility to use acryl based anti-corrosive film as a substitution of toxic corrosion inhibitors. Acryl emulsions were polymerized by several acryl monomers(acrylonitrile(AN), n-butyl acrylate(nBA), methylmethacrylate(MMA) and glycycyl methacrylate(GMA)), non-toxic corrosion inhibitor, crosslinking agents(diethylene glycol dimethacrylate(DEGDA)) and various additives in order to apply substrate of anti-corrosive film. Acryl emulsion for anti-corrosive film(AeACF) as a substrate of corrosion inhibitor film has excellent removal characteristic at above $25^{\circ}C$. The crosslinked by DEGDA in a range of above 4 wt% content anti-corrosive film can easily remove from the metal surface by using hands because it kept a balance of cohesion and adhesion strength. Anti - corrosive performance of AeACF is better than anti-corrosive oil by corrosion rate test, which was measured $54.3mg/dm^2$ day(MDD) and $142.9mg/dm^2$ day, respectively. Anti-corrosive film consisting of acryl monomers and inorganic anti-corrosive ingredients did not emit any toxic pollutants by gas chromatography. Thus it is estimated that acryl based anti-corrosion film can substitute toxic corrosion inhibitors.

• 폴리머
• /
• 제27권3호
• /
• pp.169-175
• /
• 2003

무독성의 반응형 난연 도료를 제조할 목적으로 모체수지 1개의 구조단위 속에 2개의 인산기를 보유한 파이로포스포릭 락톤 변성 폴리에스터 (PATT)를 합성하고, PATT에 이소시아네이트인 toluene diisocyanate-isocyanurate를 상온경화시켜 2성분계 폴리우레탄 난연 도료(PIPUC)를 제조하였다. PIPUC로서 도막제작 후 비난연 도료와의 도막물성을 비교한 결과 난연 성분 도입에 따른 난연 도료의 물성이 저하되지 않음을 알았다. 난연성 시험 중 45$^{\circ}$ Meckel burner 법에서는 탄화길이가 3.1~4.4 cm를, LOI법에서는 LOI 27~30%를 각각 나타냄으로써 양호한 난연 효과를 보여주었고, SEM에 의한 표면 도막을 관찰한 결과 도막의 결함이나 상분리 현상이 생기지 않음을 관찰하였다.

• 한국응용과학기술학회지
• /
• 제17권3호
• /
• pp.203-211
• /
• 2000

Pyrophosphoric lactone modified polyester(PATT) that contains two phosphorous functional groups in one unit base resin structure was synthesized to prepare a non-toxic reactive flame retardant coatings. Then the PATT was cured at room temperature with isocyanate, Desmodur IL, to get a two-component polyurethane flame retardant coatings(PIPUC). Comparing the physical properties of the films of PIPUC with the film of non-flame retardant coatings, there was no degradation observed in physical properties by the introduction of a flame-retarding component into the resin. We found that the char lengths measured by $45^{\circ}$Meckel burner method were $3.1{\sim}4.4cm$ and LOI values recorded $27{\sim}30%$. These results indicate that the coatings prepared in this study is good flame retardant one. The surface structure of coatings investigated with SEM does not show any defects and phase separation.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권10호
• /
• pp.4147-4156
• /
• 2015

Lung cancer is a serious health problem and leading cause of death worldwide due to its high incidence and mortality. More than 80% of lung cancers feature a non-small cell histology. Over few decades, systemic chemotherapy and surgery are the only treatment options in this type of tumor but due to their limited efficacy and overall poor survival of patients, there is an urge to develop newer therapeutic strategies which circumvent the problems. Enhanced knowledge of translational science and molecular biology have revealed that lung tumors carry diverse driver gene mutations and adopt different intracellular pathways leading to carcinogenesis. Hence, the development of targeted agents against molecular subgroups harboring critical mutations is an attractive approach for therapeutic treatment. Targeted therapies are clearly more preferred nowadays over systemic therapies because they target tumor specific molecules resulting with enhanced activity and reduced toxicity to normal tissues. Thus, this review encompasses comprehensive updates on targeted therapies for the driver mutations in non-small cell lung cancer (NSCLC) and the potential challenges of acquired drug resistance faced i n the field of targeted therapy along with the imminent newer treatment modalities against lung cancer.

• Radiation Oncology Journal
• /
• 제35권1호
• /
• pp.16-24
• /
• 2017

Locally advanced non-small cell lung cancer (LA-NSCLC) is composed of heterogeneous subgroups that require a multidisciplinary team approach in order to ensure optimal therapy for each patient. Since 2010, the National Comprehensive Cancer Network has recommended chemoradiation therapy (CRT) for bulky mediastinal disease and surgical combination for those patients with single-station N2 involvement who respond to neoadjuvant therapy. According to lung cancer tumor boards, thoracic surgeons make a decision on the resectability of the tumor, if it is determined to be unresectable, concurrent CRT (CCRT) is considered the next choice. However, the survival benefit of CCRT over sequential CRT or radiotherapy alone carries the risk of additional toxicity. Considering severe adverse events that may lead to death, fit patients who are able to tolerate CCRT must be identified by multidisciplinary tumor board. Decelerated approaches, such as sequential CRT or high-dose radiation alone may be a valuable alternative for patients who are not eligible for CCRT. As a new treatment strategy, investigators are interested in the application of the innovative radiation techniques, trimodality therapy combining surgery after high-dose definitive CCRT, and the combination of radiation with targeted or immunotherapy agents. The updated results and on-going studies are thoroughly reviewed in this article.

• Biomolecules & Therapeutics
• /
• 제4권4호
• /
• pp.364-372
• /
• 1996

The primary skin and eye irritation test of 0.3% DA-5018 cream, a capsaicin analogue, were carried out in rabbits. As control materials, Zostrix-HP cream (0.075% capsaicin cream) and the base of 0.3% DA-5018 cream were used in the same manners. In the primary skin irritation test, the Primary Irritation Index (P.I.I.) was 1.6, 1.9 and 0.5 in groups treated with 0.3% DA-5018 cream, Zostrix-HP cream and the base of 0.3% DA-5018 cream, respectively. The irritation ratings of 0.3% DA-5018 cream and Zostrix-HP cream were mildly irritating. The base of 0.3% DA-5018 cream was evaluated as a non-irritating material. In the eye irritation test, 0.3% DA-5018 cream and Zostrix-HP cream could be considered as mildly irritating materials. But, the base of 0.3% DA-5018 cream was a non-irritating material. These results suggest that 0.3% DA-5018 cream has mildly irritating activity and its irritancy is similar to that of Zostrix-HP cream.

• 한국산학기술학회논문지
• /
• 제15권4호
• /
• pp.2189-2198
• /
• 2014

본 연구는 제초제 음독 중에서 가장 치명률이 높은 파라쿼트 중독의 독성 감소를 위하여 파라쿼트 독성 기전으로 알려진 파라쿼트 유도성 활성산소종을 감소시키기 위해 기존의 항산화제들 치료제와는 달리, 사전에 산소 농도를 줄여서 파라쿼트에 의한 활성 산소종 발생 자체를 줄이는 저농도 산소요법의 유용성을 연구하였다. 이를 위해 백서를 활용하여 생존률 및 파라쿼트에 의한 활성 산소종의 영향을 가장 빠르고 많이 받는 폐조직의 육안적 조직학적 변화를 비교 분석함으로써 세포 독성 상황에서 저농도 산소요법의 효과를 분석하였다. 그 결과 저농도 산소요법을 처리한 군에서 유의한 생존률 증가와 함께 H&E Stain결과에서는 염증세포 증가 및 Aveolar space에 부종 소견이 저농도 산소요법을 함께 시행한 군에서 완화된 소견을 확인할 수 있었다. 또한 파라쿼트의 독성기전의 핵심인 산화스트레스발생 분석을 시행한 결과, MDA assay, Glutathione assay 및 SOD Assay모두에서 파라쿼트는 산화스트레스를 증가하지만 파라쿼트와 함께 저농도 산소요법을 처리한 경우 산화 스트레스가 감소함을 증명하였다. 이를 통해 본 연구는 임상에서 파라쿼트 중독에 대한 새로운 치료 대안으로서의 기초 연구로서 활용이 기대된다.

• 약학회지
• /
• 제57권4호
• /
• pp.258-264
• /
• 2013

Herbal medicine has been traditionally used in Asian countries for a long time. Many pharmacological effects are identified in the herbs and these herbs are believed to be safe for human. However, the safety or adverse effect of some traditional herbal medicines has not been established. We have chosen Cyperi rhizoma based on the Korea Herbal Pharmacopoeia and which have been widely used for an anti-inflammatory effect in Korea. The object of the study was to evaluate safety of Cyperi rhizoma in rats. The aqueous extract of Cyperi rhizoma was prepared according to the standard hot water extraction method of the Korea Pharmacopoeia. In the sub-chronic study, the aqueous extract of Cyperi rhizoma was orally administered once daily as 0, 125, 250, 500, 1000 and 2000 mg/kg/day to male and female F344 rats for 13 weeks. There were no treatment related abnormalities in mortality, clinical signs, food consumption, ophthalmologic examination, hematology, serum chemistry, urinalysis, gross observation, organ weight and histopathologic examination. In conclusion, The NOAEL (No Observed Adverse Effect Level) for Cyperi rhizoma aqueous extract was determined as more than 2000 mg/kg/day in the present experimental condition.

• 한국세라믹학회지
• /
• 제48권6호
• /
• pp.537-542
• /
• 2011

Magnesium hydroxide as a non-halogen flame retardant has increasing attention due to its non-toxicity, high decomposition temperature and smoke suppressant ability during combustion. For the application of magnesium hydroxide retardant to the textile by soaking and coating method, the prerequisite for the coating is a small particle size, stable dispersion, and adhesion to the textile. The dispersion of $Mg(OH)_2$ particles and stability of the coating was checked by monitoring the change of transmittance and backscattering by varying the types of dispersion agents, binder, solvent, and $Mg(OH)_2$ source, and their compositions in the coating. The $Mg(OH)_2$ dispersion coating was applied to PET(poly(ethylene terephthalate)) non-woven textile. The physical properties are characterized by surface morphology, amount of coating, particle dispersion, and adhesion test. The flame retardant $Mg(OH)_2$ coated textile has been compared by limited oxygen index(LOI) and thermal gravimetry and differential scanning calorimetry(TG-DSC). It was found that phosphorous additive may give synergistic effect on $Mg(OH)_2$ flame retardant coating to make the flame retardant PET non-woven textile.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권14호
• /
• pp.5945-5950
• /
• 2014

Objectives: To retrospectively review the safety and clinical efficacy of bevacizumab concomitant with chemotherapy in Chinese patients with advanced non-squamous non-small cell lung cancer (NSNSCLC). Methods: Clinical data for 79 patients with NSNSCLC who received bevacizumab concomitant with chemotherapy in Chinese PLA General Hospital from April 28th 2009 to May 5th 2013 were retrospectively reviewed to analyze the clinical efficacy including disease control rate (DCR), overall response rate (ORR), progression-free survival (PFS), overall survival (OS), the Eastern Cooperative Oncology Group (ECOG) score and the safety. Results: The Eastern Cooperative Oncology Group (ECOG) score was 0-2. By the final cutoff date (June 9, 2013), 54 (68.4%) patients had disease progression and 37 (46.8%) died. The ORR was 32.9% and the DCR was 83.5%. The ORR of the first-, second-, and third- or later-line treatments were 51.4%, 25.0% and 12.5%, while the DCR were 94.3%, 80.0% and 70.8%, respectively. The median OS (mOS) and PFS (mPFS) were 13.5 and 5.83 months, respectively. The mOS of patients with the first-, second-, and third- or later- line treatments were 16.2, 10.9 and 8.30 months, while the mPFS were 7.27, 5.90 and 5.17 months, respectively. Chemotherapy-related adverse events included myelosuppression, vomiting, hepatic dysfunction and renal dysfunction, while the common serious bevacizumab-related adverse events were thromboembolic problems, gastrointestinal perforation and reversible posterior leukoencephalopathy syndrome, which could be well managed. Conclusions: Bevacizumab concomitant with chemotherapy is effective and the related toxicity can be well tolerated in Chinese patients with NSNSCLC.